ExodusPoint Capital Management LP Has $389,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

ExodusPoint Capital Management LP lifted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 71.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,691 shares of the company’s stock after acquiring an additional 6,958 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Spyre Therapeutics were worth $389,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Huntington National Bank bought a new position in Spyre Therapeutics in the fourth quarter valued at approximately $34,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Spyre Therapeutics in the fourth quarter valued at $46,000. KLP Kapitalforvaltning AS bought a new position in shares of Spyre Therapeutics in the fourth quarter valued at $182,000. Arizona State Retirement System increased its holdings in Spyre Therapeutics by 38.4% during the fourth quarter. Arizona State Retirement System now owns 10,115 shares of the company’s stock worth $235,000 after buying an additional 2,805 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Spyre Therapeutics during the fourth quarter worth $242,000. Institutional investors own 80.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SYRE shares. Wolfe Research assumed coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $27.00 price objective for the company. The Goldman Sachs Group upgraded Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Leerink Partners began coverage on Spyre Therapeutics in a research note on Tuesday, April 8th. They issued an “outperform” rating and a $45.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $65.00 target price on shares of Spyre Therapeutics in a research note on Monday, January 13th. Finally, Leerink Partnrs upgraded Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, April 8th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Spyre Therapeutics currently has an average rating of “Buy” and a consensus price target of $49.57.

Spyre Therapeutics Trading Up 2.4 %

NASDAQ:SYRE opened at $12.22 on Friday. The stock has a 50 day simple moving average of $18.46 and a 200 day simple moving average of $24.29. Spyre Therapeutics, Inc. has a 1-year low of $10.91 and a 1-year high of $40.84. The stock has a market cap of $736.34 million, a P/E ratio of -1.64 and a beta of 3.05.

Spyre Therapeutics (NASDAQ:SYRE) last posted its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.08. As a group, sell-side analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).